Paradromics, a U.S.-based brain-computer interface (BCI) company, has recently secured approval from the U.S. Food and Drug Administration (FDA) to embark on its inaugural long-term clinical trial. Early next year, the company intends to implant BCI devices in two volunteers who have suffered a loss of speech ability. The primary goal is to verify the safety of these devices and to restore the patients' capacity for real-time verbal communication. The BCI device in question is equipped with built-in electrodes made of a platinum-iridium alloy, which can precisely record the activity of individual neurons.

The trial will also delve into the possibility of enabling volunteers to manipulate a computer cursor using only their thoughts. There is potential for the trial to expand to include up to 10 volunteers in the future. In addition, other U.S. firms such as Synchron and Neuralink have also been making strides in the realm of brain-computer interfaces. These companies are striving to make the implantation process less invasive and to ensure that the devices can be easily replaced when necessary.

Paradromics has stated its commitment to continuing its focus on safety and other critical aspects. It highlighted that its device boasts an information transmission rate outside the brain that is roughly 20 times greater than that of competing devices, with an expected lifespan exceeding a decade. Clinicians and neuroscientists will be closely observing and comparing the effects of each device. Some experts have expressed the hope that companies will uphold transparency and make their devices available to the academic community for further research and development.